Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

genzyme australasia pty ltd - imiglucerase -

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - velaglucerase alfa - gaucher disease - other alimentary tract and metabolism products, - vpriv is indicated for long-term enzyme-replacement therapy (ert) in patients with type-1 gaucher disease.

Իսրայել - անգլերեն - Ministry of Health

takeda israel ltd - velaglucerase alfa - lyophilized powder for solution for infusion - velaglucerase alfa 400 u/vial - velaglucerase alfa - velaglucerase alfa - vpriv is a hydrolytic glucocerebroside – specific enzyme indicated for the long term replacement therapy (ert) for pediatric and adult patients with type 1 gaucher disease.

Իսրայել - անգլերեն - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - powder for solution for infusion - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso™ (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ert) for adults and pediatric patients with a confirmed diagnosis of type 1 gaucher disease

Իսրայել - անգլերեն - Ministry of Health

j-c health care ltd - miglustat - capsules - miglustat 100 mg - miglustat - miglustat - zavesca is indicated for the oral treatment of mild to moderate type i gaucher disease. zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

piramal critical care b.v. - miglustat - gaucher disease - other alimentary tract and metabolism products, - yargesa is indicated for the oral treatment of adult patients with mild to moderate type 1 gaucher disease.yargesa may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.yargesa is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

janssen cilag international nv - miglustat - gaucher disease; niemann-pick diseases - other alimentary tract and metabolism products, - zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 gaucher disease. zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type-c disease.

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

actelion pharmaceuticals uk ltd - miglustat - capsule - 100mg

Միացյալ Թագավորություն - անգլերեն - MHRA (Medicines & Healthcare Products Regulatory Agency)

shire pharmaceuticals ltd - velaglucerase alfa - powder for solution for infusion - 400unit

Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

gen.orph - miglustat - gaucher disease - other alimentary tract and metabolism products, - miglustat gen.orph is indicated for the oral treatment of adult patients with mild to moderate type 1 gaucher disease. miglustat gen.orph may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.miglustat gen.orph is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with niemann-pick type c disease.